Skip to main content
SpringerLink
Log in

Editorial: what is the role of antiandrogen therapy in the treatment of prostate cancer?

  • Editorial
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  • Aus G, Abbou CC, Bolla M, Heidenreich A, Van Poppel H, Schmid H-P, Wolff JM, Zattoni F (2005) European Association of Urology Guidelines on Prostate Cancer (accessed 19 December 2005, through http://www.uroweb.nl/files/uploaded_files/2005Prostate%20Cancer.pdf)

  • Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F (2005) Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 23:808–815

    Article  PubMed  CAS  Google Scholar 

  • Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Cutajar CL, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–108

    Article  PubMed  CAS  Google Scholar 

  • Iversen P, Tammela TLJ, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P, Lundmo P, Rasmussen F, Johansson J-E, Persson B-E, Carroll K, Scandinavian Prostatic Cancer Group (SPCG) (2002) A randomised comparison of bicalutamide (‘Casodex’) 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group study no. 6. Eur Urol 42:204–211

    Article  PubMed  CAS  Google Scholar 

  • Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I (2000) Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 164:1579–1582

    Article  PubMed  CAS  Google Scholar 

  • Jenkins V, Fallowfield L, Edginton T, Payne H, Hamilton E (2005) Preferences of healthy men for two different endocrine treatment options offered for locally advanced prostate cancer. Curr Med Res Opin 21:1329–1335

    Article  PubMed  CAS  Google Scholar 

  • McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, on behalf of the ‘Casodex’ Early Prostate Cancer Trialists’ Group (2006) Bicalutamide 150 mg plus standard care versus standard care alone for early prostate cancer. BJU Int 97:247–254

  • Pilepich MV, Winter K, Lawton CA, Krish RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D (2005) Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate—long term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys 61:1285–1290

    PubMed  CAS  Google Scholar 

  • See WA, McLeod D, Iversen P, Wirth M (2001) The bicalutamide Early Prostate Cancer program: demography. Urol Oncol 6:43–47

    Article  PubMed  Google Scholar 

  • Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S (2004) Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 171:2272–2276

    Article  PubMed  CAS  Google Scholar 

  • Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De BC, Andersson SO, Morris T, Carroll K (2004) Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 60:476–483

    Google Scholar 

  • Van Poppel H, Tyrrell CJ, Haustermans K, Cangh PV, Keuppens F, Colombeau P, Morris T, Garside L (2005) Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol 47:587–592

    Article  PubMed  Google Scholar 

  • Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M (2004) Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 45:267–270

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The EPC program was funded by AstraZeneca. We thank Dr Sarah Goodger from Complete Medical Group, who provided medical writing support on behalf of AstraZeneca.

Author information

Authors and Affiliations

  1. Meyerstein Institute of Oncology, Middlesex Hospital, Mortimer Street, London, W1T 3AA, UK

    Heather Payne

Authors
  1. Heather Payne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heather Payne.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Payne, H. Editorial: what is the role of antiandrogen therapy in the treatment of prostate cancer?. J Cancer Res Clin Oncol 132 (Suppl 1), 1–6 (2006). https://doi.org/10.1007/s00432-006-0131-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-006-0131-7

Search

Navigation